Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results
Author(s)
Type
Journal Article
Abstract
The United Kingdom (UK) is in the third season of
introducing universal paediatric influenza vaccination
with a quadrivalent live attenuated influenza
vaccine (LAIV). The 2015/16 season in the UK was initially
dominated by influenza A(H1N1)pdm09 and then
influenza of B/Victoria lineage, not contained in that
season’s adult trivalent inactivated influenza vaccine
(IIV). Overall adjusted end-of-season vaccine effectiveness
(VE) was 52.4% (95% confidence interval (CI):
41.0–61.6) against influenza-confirmed primary care
consultation, 54.5% (95% CI: 41.6–64.5) against influenza
A(H1N1)pdm09 and 54.2% (95% CI: 33.1–68.6)
against influenza B. In 2–17 year-olds, adjusted VE
for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any
influenza, 81.4% (95% CI: 39.6–94.3) against influenza
B and 41.5% (95% CI: −8.5 to 68.5) against influenza
A(H1N1)pdm09. These estimates demonstrate moderate
to good levels of protection, particularly against
influenza B in children, but relatively less against
influenza A(H1N1)pdm09. Despite lineage mismatch
in the trivalent IIV, adults younger than65 years were
still protected against influenza B. These results provide
reassurance for the UK to continue its influenza
immunisation programme planned for 2016/17.
introducing universal paediatric influenza vaccination
with a quadrivalent live attenuated influenza
vaccine (LAIV). The 2015/16 season in the UK was initially
dominated by influenza A(H1N1)pdm09 and then
influenza of B/Victoria lineage, not contained in that
season’s adult trivalent inactivated influenza vaccine
(IIV). Overall adjusted end-of-season vaccine effectiveness
(VE) was 52.4% (95% confidence interval (CI):
41.0–61.6) against influenza-confirmed primary care
consultation, 54.5% (95% CI: 41.6–64.5) against influenza
A(H1N1)pdm09 and 54.2% (95% CI: 33.1–68.6)
against influenza B. In 2–17 year-olds, adjusted VE
for LAIV was 57.6% (95% CI: 25.1 to 76.0) against any
influenza, 81.4% (95% CI: 39.6–94.3) against influenza
B and 41.5% (95% CI: −8.5 to 68.5) against influenza
A(H1N1)pdm09. These estimates demonstrate moderate
to good levels of protection, particularly against
influenza B in children, but relatively less against
influenza A(H1N1)pdm09. Despite lineage mismatch
in the trivalent IIV, adults younger than65 years were
still protected against influenza B. These results provide
reassurance for the UK to continue its influenza
immunisation programme planned for 2016/17.
Date Issued
2016-09-22
Date Acceptance
2016-08-30
Citation
Eurosurveillance, 2016, 21 (38), pp.41-51
ISSN
1560-7917
Publisher
European Centre for Disease Prevention and Control
Start Page
41
End Page
51
Journal / Book Title
Eurosurveillance
Volume
21
Issue
38
Copyright Statement
This is an open-access article distributed under the terms of
the Creative Commons Attribution (CC BY 4.0) Licence. You
may share and adapt the material, but must give appropriate
credit to the source, provide a link to the licence, and indicate
if changes were made.
This article is copyright of the authors, 2016.
the Creative Commons Attribution (CC BY 4.0) Licence. You
may share and adapt the material, but must give appropriate
credit to the source, provide a link to the licence, and indicate
if changes were made.
This article is copyright of the authors, 2016.
License URL
Subjects
Science & Technology
Life Sciences & Biomedicine
Infectious Diseases
VIRUS
TIME
AGE
STATES
PCR
Publication Status
Published
Article Number
30348